Laryngeal Cancer Medical Services in China

Laryngeal cancer is a malignant neoplasm arising from the epithelial cells of the larynx—most commonly the glottis (vocal cords), followed by the supraglottis and subglottis. Risk factors include tobacco use, heavy alcohol consumption, human papillomavirus (HPV) infection (particularly for supraglottic tumors), and occupational exposure to carcinogens. Clinical presentation often includes persistent hoarseness, dysphagia, odynophagia, referred otalgia, or a neck mass due to nodal metastasis. Diagnosis relies on flexible laryngoscopy with biopsy, supplemented by cross-sectional imaging (contrast-enhanced CT or MRI) and PET-CT for staging. Treatment is stage-dependent: early-stage (T1–T2) disease may be managed with transoral laser microsurgery (TLM) or radiotherapy alone; locally advanced cases (T3–T4 or N+), however, typically require multimodal therapy—including concurrent chemoradiation or organ-preserving protocols, or total laryngectomy with neck dissection when indicated.

China offers distinct advantages for international patients seeking laryngeal cancer care. Leading oncology centers—such as Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center—employ multidisciplinary tumor boards, utilize cutting-edge technologies including robotic-assisted TLM, intensity-modulated radiation therapy (IMRT), and next-generation sequencing for molecular profiling. Five-year survival rates for early-stage laryngeal cancer exceed 85% in these institutions, supported by robust clinical evidence published in journals like *Head & Neck* and *Oral Oncology*. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising quality—due to streamlined healthcare delivery and government-subsidized infrastructure. As a dedicated medical tourism agency, we facilitate seamless access for international patients: coordinating appointments with certified ENT oncologists, verifying hospital accreditation and surgeon credentials, providing itemized, transparent pricing in advance, and delivering end-to-end support—from visa assistance and accommodation to post-treatment follow-up coordination and multilingual interpretation.

Treatment Options & Itemized Cost Breakdown for Laryngeal Cancer (Oncology Department)

Non-Surgical / Conservative / Medication Options

*Indicated for early-stage (T1–T2, N0), medically inoperable patients, or as neoadjuvant/adjuvant therapy.*

• •Radiation Therapy (IMRT/VMAT): Primary curative modality for T1–T2 glottic cancer.

- Daily fraction (30 fractions): $4,200–$5,600 (total course) - Weekly blood tests (CBC, liver/kidney function): $45–$65/session × 6 sessions = $270–$390

• •Chemotherapy (Cisplatin-based concurrent CRT): For locally advanced (T3–T4/N+) disease.

- Antiemetics, hydration, electrolyte monitoring: $220–$310/cycle → $660–$930 total

• •Immunotherapy (Pembrolizumab): For recurrent/metastatic PD-L1+ disease (CPS ≥1).

- Baseline PD-L1 IHC testing: $290 - Monthly thyroid/LFT monitoring: $130–$180/month

Surgical / Procedural / Interventional Options

*Eligibility: Resectable disease (T1–T4, N0–N2), adequate pulmonary/cardiac reserve, no distant metastasis.*

• •Transoral Laser Microsurgery (TLM): Gold standard for T1–T2 glottic/supraglottic cancers.

- Procedure (CO₂ laser resection + frozen section): $3,900–$5,100

• •Partial Laryngectomy (Horizontal/Vertical): For T3/T4 with cartilage invasion.

- Surgery + 5-day ICU/stay: $6,800–$8,400

• •Total Laryngectomy + Neck Dissection: For unresectable local disease or salvage after failed RT.

- Surgery + 7-day post-op care + stoma care training: $9,200–$11,600

Special / Complex Condition Options

• •Recurrent/Residual Disease Post-RT: Salvage TLM or total laryngectomy — add $1,100–$1,500 for repeat imaging and functional assessment.
• •Nodal Metastasis (N2c/N3): Modified radical neck dissection + adjuvant CRT — adds $2,400–$3,100 to base surgical cost.
• •Tracheoesophageal Puncture (TEP) + Voice Prosthesis: For voice rehabilitation post-total laryngectomy — $1,350–$1,780 (procedure + prosthesis + speech therapy x4 sessions).

Quick Selection Guide

• •<65 years, T1–T2, no comorbidities: TLM ($3,900–$5,100) — optimal functional preservation, lowest recurrence risk.
• •≥75 years or severe COPD/CHF: Definitive IMRT ($4,200–$5,600) — avoids anesthesia risk; includes supportive lab monitoring.
• •T3–T4 with cartilage involvement: Partial laryngectomy ($6,800–$8,400) — superior oncologic control vs. RT alone.
• •Budget-constrained (≤$5,000): Concurrent CRT ($4,000–$5,300) — balances efficacy and affordability for locally advanced disease.
• •PD-L1+ recurrent/metastatic: Pembrolizumab monotherapy ($1,850–$2,200/dose) — first-line if platinum-ineligible; requires confirmatory IHC ($290).